Sex Steroids Regulate Expression of Genes Containing Long Interspersed Elements-1s in Breast Cancer Cells

  • Chaiwongwatanakul, Saichon (Department of Biological Sciences, Faculty of Science, Chulalongkorn University) ;
  • Yanatatsaneejit, Pattamawadee (Human Genetics Research Group, department of Botany, Faculty of Sciences, Chulalongkorn University) ;
  • Tongsima, Sissades (Biostatistics and Informatics Laboratory, Genome Institute, National Center for Genetic Engineering and Biotechnology) ;
  • Mutirangura, Apiwat (Center of Excellence in Molecular Genetics of Cancer and Human Diseases, Department of Anatomy, Faculty of Medicine, Chulalongkorn University) ;
  • Boonyaratanakornkit, Viroj (Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University)
  • 발행 : 2016.08.01


Long interspersed elements-1s (LINE-1s) are dispersed all over the human genome. There is evidence that hypomethylation of LINE-1s and levels of sex steroids regulate gene expression leading to cancer development. Here, we compared mRNA levels of genes containing an intragenic LINE-1 in breast cancer cells treated with various sex steroids from Gene Expression Omnibus (GEO), with the gene expression database using chi-square analysis ( We evaluated whether sex steroids influence expression of genes containing an intragenic LINE-1. Three sex steroids at various concentrations, 1 and 10 nM estradiol (E2), 10 nM progesterone (PG) and 10 nM androgen (AN), were assessed. In breast cancer cells treated with 1 or 10 nM E2, a significant percentage of genes containing an intragenic LINE-1 were down-regulated. A highly significant percentage of E2-regulated genes containing an intragenic LINE-1 was down-regulated in cells treated with 1 nM E2 for 3 hours (p<3.70E-25; OR=1.91; 95% CI=2.16-1.69). Similarly, high percentages of PG or AN-regulated genes containing an intragenic LINE-1 wwere also down-regulated in cells treated with 10 nM PG or 10 nM AN for 16 hr (p=9.53E-06; OR=1.65; 95% CI=2.06-1.32 and p=3.81E-14; OR=2.01; 95% CI=2.42-1.67). Interestingly, a significant percentage of AN-regulated genes containing an intragenic LINE-1 was up-regulated in cells treated with 10 nM AN for 16 hr (p=4.03E-02; OR=1.40; 95% CI=1.95-1.01). These findings suggest that intragenic LINE-1s may play roles in sex steroid mediated gene expression in breast cancer cells, which could have significant implications for the development and progression of sex steroid-dependent cancers.


연구 과제 주관 기관 : Thailand Graduate Institute of Science and Technology (TGIST), National Science and Technology Development Agency (NSTDA), Chulalongkorn University


  1. Aporntewan C, Phokaew C, Piriyapongsa J, et al (2011). Hypomethylation of intragenic LINE-1 represses transcription in cancer cells through AGO2. PloS one, 6, 1-13.
  2. Aranda A, Pascual A (2001). Nuclear hormone receptors and gene expression. Phys Rev, 81, 1269-304.
  3. Brinton LA, Key TJ, Kolonel LN (2015). Prediagnostic Sex steroid hormones in relation to male breast cancer risk. J Clin Oncol, 1-14.
  4. Brouha B, Schustak J, Badge RM, et al (2003). Hot L1s account for the bulk of retrotransposition in the human population. Proc Natl Acad Sci USA, 100, 5280-5.
  5. Buzdar AU (2003). Breast cancer in men. Oncol, 17, 1361-4.
  6. Chalitchagorn K, Shuangshoti S, Hourpai1 N, et al (2004). Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis. Oncogene, 23, 8841-6
  7. Cho YH, Yazici H, Wu HC, et al (2010). Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients. Anticancer Res, 30, 2489-6.
  8. Dickson RB, Stancel GM (2000). Estrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst Monogr, 27, 135-45.
  9. Ding W, Lin L, Chen B, Dai J (2006). L1 elements, processed pseudogenes and retrogenes in mammalian genomes. IUBMB Life, 58, 677 - 85.
  10. Edgar R, Domrache, M, Lash AE (2002). Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res, 30, 207-10.
  11. Esnault C, Maestre J, Heidmann T (2004). Human LINE retrotransposons generate processed pseudogenes. Nat Genet, 24, 363-67.
  12. Florl AR, Lower R, Schmitz-Drager BJ, Schulz WA (1999). DNA methylation and expression of LINE-1 and HERV-K provirussequences in urothelial and renal cell carcinomas. Br J Cancer, 80, 1312-21.
  13. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN (2004). Breast carcinoma in men: a population-based study. Cancer, 101, 51-7.
  14. Han JS, Szak ST, Boeke JD (2004). Transcriptional disruption by the L1 retrotransposon And implications for mammalian transcriptomes. Nature, 429, 268-74.
  15. Hosseini A, Gopalan V, Nassiri M, et al (2014). Estrogen receptor alpha gene expression in breast cancer tissues from the Iranian population--a pilot study. Asian Pac J Cancer Prev, 15, 8789-91.
  16. Kato S, Sato T, Watanabe T, et al (2005). Function of nuclear sex hormone receptors in gene regulation. Cancer Chemother Pharmacol, 1, 4-9.
  17. Kazazian HH Jr, Moran JV (1998). The impact of L1 retrotransposons on the human genome. Nat Genet, 19, 19-24.
  18. Khowutthitham S, Ngamphiw C, Wanichnopparat W, et al (2012). Intragenic long interspersed element-1 sequences promote promoter hypermethylation in lung adenocarcinoma, multiple myeloma and prostate cancer. Genes Genom, 34, 517-528.
  19. Kitkumthorn N, Mutirangura A (2011). Long interspersed nuclear element-1 hypomethylation in cancer: biology and clinical applications. Clin Epigenet, 2, 315-30.
  20. Lin CY, Vega VB, Thomse JS, et al (2007b). Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet, 3, 867-85.
  21. Lin Z, Reierstad S, Huang CC, Bulun SE (2007a). Novel estrogen receptor-alpha binding sites And estradiol target genes identified by chromatin immunoprecipitation cloning in breast cancer. Cancer Res, 67, 5017-24.
  22. Maggiolini M, Picard D (2010). The unfolding stories of GPR30, a new member-bound estrogen receptor. J endocrinol, 204, 105-14.
  23. Matlik K, Redik K, Speek M (2006). L1 antisense promoter drives tissue-specific transcription of human genes. J Biomed Biotechnol, 1, 1-16.
  24. Need EF, Selth LA, Trotta AP, et al (2015). The unique transcriptional response produced by concurrent estrogen and progesterone treatment in breast cancer cells results in upregulation of growth factor pathways and switching from a Luminal A to a Basal-like subtype. BMC Cancer, 15, 1-17.
  25. Ngamphiw C, Tongsima S,Mutirangura, A (2014). Roles of intragenic and intergenic L1s in mouse and human. PloS one, 8, 1-8.
  26. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR (2005). Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol, 23, 21-7.
  27. Penzkofer T, Dandekar T, Zemojtel T (2005). L1Base: from functional annotation to prediction of active LINE-1 elements. Nucleic Acids Res, 33, 498-500.
  28. Prenzel T, Begus-Nahrmann Y, Kramer F, et al (2011). Estrogendependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B. Cancer Res, 71, 5739-53.
  29. Puzianowska-Kuznicka M, Pawlik-Pachucka E, Owczarz M, Budzinska M, Polosak J (2013). Small-molecule hormones: molecular mechanisms of action. Int J Endocrinol, 2013, 1-21.
  30. Quigley CA, De Bellis A, Marschk, KB, et al (1995). Androgen receptor defects: histological, clinical, and molecular perspectives. Endocr Rev, 16, 271-321.
  31. Ralston A, Shaw K (2008). Gene expression regulates cell differentiation. Nat Educ, 1, 127-31.
  32. Shandiz FH, Tavassoli A, Sharifi N, et al (2015). Hormone receptor expression and clinicopathologic features in male and female breast cancer. Asian Pac J Cancer Prev, 16, 471-4.
  33. Sieri S, Krogh V, Bolelli G, et al (2009). Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort. Cancer Epidemiol Biomarkers Prev, 18, 169-76.
  34. Stanisic V, Lonard DM, O'Malley BW (2010). Modulation of steroid hormone receptor activity. Prog Brain Res, 181, 153-76.
  35. Tangkijvanich P, Hourpai N, Rattanatanyong P, et al (2007). Serum LINE-1 hypomethylation as a potential prognostic marker for hepatocellular carcinoma. Clin Chim Acta, 379, 127-33.
  36. Wanichnopparat W, Suwanwongse K, Pin-on P, Aporntewan C, Mutirangura A (2013). Genes associated with the cisregulatory functions of intragenic LINE-1 elements. BMC Genomics, 14, 1-9.
  37. Weber B, Kimhi S, Howard G, Eden A, Lyko F (2010). Demethylation of a LINE-1 antisense promoter in the cMet locus impairs Met signalling through induction of illegitimate transcription. Oncogene, 29, 5775-84.
  38. Wierman ME (2007). Sex steroid effects at target tissues: mechanisms of action. Adv Physiol Educ, 31, 26-33.
  39. Xiao-Jie L, Hui-Ying X, Qi X, Jiang X, Shi-Jie M (2016). LINE- 1 in cancer: multifaceted functions and potential clinical implications. Genet Med, 18, 431-39.
  40. Yang BH, Parkin DM, Cai L, Zhang Z (2004). Cancer burden and trends in the Asian Pacific Rim region. Asian Pac J Cancer Prev, 5, 96-117.